Table 2 Summary of efficacy outcomes
Variables | RT + PD1, N = 37 (%) | TACE + Sorafenib, N = 41(%) | P value |
|---|---|---|---|
According to RECIST 1.1 | |||
Confirmed objective response | 20 (54.05%) | 5(12.20%) |  < 0.001 |
Time to response, months, (IQR) | 1.80(1.57–2.00) | 2.87(1.407–6.86) | 0.467 |
Disease control | 26(70.27%) | 19(46.34%) | 0.041 |
Best overall response | |||
  CR | 0(0) | 0(0) | 1.000 |
  PR | 20 (54.05%) | 5(12.20%) |  < 0.001 |
  SD | 6(16.22%) | 14(34.15%) | 0.118 |
  PD | 11(29.73%) | 22(53.66%) | 0.041 |
Progression-free survival, months, median, (95% CI) | 5.86(3.19–8.53) | 3.70(2.60–4.80) | 0.017 |
According to mRECIST | |||
Confirmed objective response | 21(56.76%) | 13(31.71%) | 0.039 |
Time to response, months, (IQR) | 1.85(1.60–2.98) | 1.47(0.80–2.60) | 0.061 |
Disease control | 26(70.27%) | 19(46.34%) | 0.041 |
Best overall response | |||
  CR | 1(2.70%) | 1(2.44%) | 1.000 |
  PR | 20 (54.05%) | 12(29.27%) | 0.038 |
  SD | 5(13.51%) | 6(14.63%) | 0.774 |
  PD | 11(29.73%) | 22(53.66%) | 0.041 |
Progression-free survival, months, median, (95% CI) | 5.86(3.19–8.53) | 3.70(2.60–4.80) | 0.019 |
Overall survival | |||
3-month, % | 97.30% | 92.30% |  < 0.001 |
6-month, % | 91.90% | 68.60% |  < 0.001 |
9-month, % | 75.50% | 60.60% |  < 0.001 |
12-month, % | 52.20% | 47.5% | 0.061 |
Overall survival, months, median, (95% CI) | 17.40 (8.69–26.11) | 11.90 (6.35–17.45) | 0.146 |